Boxer Capital’s Cogent Biosciences COGT Stock Holding History

Boxer Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-525,000	Closed	-$5.12M	–	58
2023 Q3	$5.12M	Hold	525,000	–	–	0.27%	51
2023 Q2	$6.22M	Hold	525,000	–	–	0.29%	53
2023 Q1	$5.67M	Hold	525,000	–	–	0.28%	47
2022 Q4	$6.07M	Buy	525,000 +100,000	+24%	+$1.24M	0.32%	47
2022 Q3	$6.34M	Hold	425,000	–	–	0.36%	49
2022 Q2	$3.83M	Buy	+425,000	New	+$2.9M	0.24%	61

Other funds holding COGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital's COGT Position: Q4 2023 in Review

Boxer Capital sold out of Cogent Biosciences (COGT) in Q4 2023, closing a stake of 525,000 shares — an estimated $5.12M sold.

Boxer Capital first reported a position in COGT in Q2 2022 and held it in 6 quarters. The position peaked at $6.34M in Q3 2022. 144 funds tracked by Wall St. Rank hold COGT as of Q4 2023.

Boxer Capital reported no remaining Cogent Biosciences position as of Q4 2023 after selling out during the quarter.
Boxer Capital sold 525,000 Cogent Biosciences shares in Q4 2023, an estimated $5.12M.
Boxer Capital first reported a position in Cogent Biosciences in Q2 2022 and held it in 6 quarters.
Boxer Capital's Cogent Biosciences position peaked at $6.34M in Q3 2022.
144 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2023.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.